The Technical Analyst
Iovance Biotherapeutics [IOVA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Iovance Biotherapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.91% $11.15
America/New_York / 19 apr 2024 @ 14:15
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 112.88 mill |
| EPS: | -1.890 |
| P/E: | -5.90 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 279.31 mill |
| Avg Daily Volume: | 9.12 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.90 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.00x |
| Company: PE -5.90 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.201 (-98.20%) $-10.94 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.13 - 12.22 ( +/- 9.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Vogt Frederick G | Buy | 20 834 | Common Stock |
| 2024-04-15 | Vogt Frederick G | Sell | 8 851 | Common Stock |
| 2024-04-15 | Vogt Frederick G | Sell | 20 834 | Restricted Stock Units |
| 2024-04-15 | Graf Finckenstein Friedrich | Buy | 2 812 | Common Stock |
| 2024-04-15 | Graf Finckenstein Friedrich | Sell | 1 427 | Common Stock |
| INSIDER POWER |
|---|
| 94.64 |
| Last 99 transactions |
| Buy: 13 607 426 | Sell: 449 378 |
Forecast:
15:55 - $11.15
Live Trading Signals (every 1 min)
Forecast
1: 14:25 - $11.14
Forecast 2: 15:15 - $11.18
Forecast 3: 15:55 - $11.15
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.15 (-4.91% ) |
| Volume | 3.16 mill |
| Avg. Vol. | 9.12 mill |
| % of Avg. Vol | 34.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IOVA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $8.70 | N/A | Active |
|---|
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Latest Press Releases
2024-03-22 17:30:00 - Press Release
Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San carlos, calif., march 22, 2024 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova) ("iovance" or the “company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (til) therapies for patients with cancer, today announced that on march 22, 2024 (the “date of grant”), the company approved the grant of inducement stock options covering an aggregate of 97,700 shares of iovance's common stock to twenty new, non-executive employees.
2024-03-04 06:30:00 - Press Release
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold On The Iov-lun-202 Registrational Trial In Non-small Cell Lung Cancer
San carlos, calif., march 04, 2024 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (til) therapies for patients with cancer, today announced that the u.s. food and drug administration (fda) lifted a partial clinical hold placed on the registrational iov-lun-202 trial investigating ln-145 til cell therapy in non-small cell lung cancer (nsclc). in collaboration with the fda and an independent data monitoring committee, iovance developed additional safety measures and monitoring. upon reviewing this proposal, the fda has cleared iovance to resume patient enrollment in iov-lun-202.
2024-03-01 17:00:00 - Press Release
Iovance Biotherapeutics To Present At Upcoming Conferences
San carlos, calif., march 01, 2024 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (til) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
2024-02-28 16:01:00 - Press Release
Iovance Biotherapeutics Reports Fourth Quarter And Full Year 2023 financial Results And Corporate Updates
Amtagvi™ (lifileucel) u.s. launch fully underway following u.s. food and drug administration (fda) approval as the first and only one-time, individualized t cell therapy for a solid tumor cancer
2024-02-22 08:45:00 - Press Release
Iovance Biotherapeutics To Host Fourth Quarter And Full-year 2023 Financial Results Conference Call And Webcast On Wednesday, February 28, 2024
San carlos, calif., feb. 22, 2024 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (til) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on wednesday, february 28, 2024. management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. et.
Latest News
2024-04-17 09:45:00 - The Motley Fool
Is Iovance Biotherapeutics Stock a Buy Now?
Iovance Biotherapeutics has a novel approach to developing cancer medicines. The small biotech recently earned approval for an important product.
2024-04-09 07:01:31 - MarketBeat
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.
2024-04-09 06:05:54 - Seeking Alpha
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production capacity and aims to become a global leader in TIL therapies for cancer patients. Insider ownership has increased by over 50%, indicating strong confidence in the company's future results.
2024-04-08 14:56:06 - Zacks Investment Research
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
2024-04-05 05:03:00 - The Motley Fool
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.
2024-03-26 04:11:00 - The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
The Nasdaq Composite index is up sharply over the past year, but it contains at least two growth stocks poised to run even higher. Investment bank analysts who follow Viking Therapeutics think the stock can gain another 47% following a big run-up.
2024-03-18 20:01:33 - InvestorPlace
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
2024-03-06 04:42:00 - The Motley Fool
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
Iovance Biotherapeutics is commercializing its first therapy. The product will be fairly expensive to manufacture and distribute.
2024-03-05 14:01:19 - Zacks Investment Research
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
2024-03-02 06:50:00 - The Motley Fool
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.